Neumora Therapeutics NMRA
NASDAQ NMRA
$0.47 +0.01 (+1.37%)
At close: Nov 11, 2026 · 4:00 PM EST

Neumora Therapeutics (NMRA) Gains from Sales and Divestitures (2025 - 2026)

Updated

Neumora Therapeutics (NMRA) recorded Gains from Sales and Divestitures of $71,000 in Q1 2026.

Analysis

Neumora Therapeutics (NMRA) Gains from Sales and Divestitures (2025 - 2026) Analysis & Trends

For FY2025, Neumora Therapeutics reported Gains from Sales and Divestitures of -$47,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neumora Therapeutics 88.31 Mn -529.65 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 71,000.00
Jun 30, 2025 -62,000.00
API Access

Neumora Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=NMRA&period=max&api_key=YOUR_API_KEY